Fast Market Research

New Market Report Now Available: Diquas (Dry Eye Syndrome) - Forecast and Market Analysis to 2022

Fast Market Research recommends "Diquas (Dry Eye Syndrome) - Forecast and Market Analysis to 2022" from GlobalData, now available

 

Boston, MA -- (SBWIRE) -- 09/30/2013 -- Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

View Full Report Details and Table of Contents

Diquas ophthalmic solution 3%, developed by Santen Pharmaceutical, is the first approved P2Y2 receptor agonist to be formulated as an ophthalmic solution for the treatment of DES. It improves dry eye symptoms by promoting the secretion of natural tear elements - mucin, lipids, and water - to significantly improve tear production.

Scope

- Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Diquas including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Diquas for the top two countries from 2012 to 2022.
- Sales information covered for Japan and China.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for DES
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Diquas performance
- Obtain sales forecast for Diquas from 2012-2022 in top two countries (Japan and China)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022
- EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022